Just curious if you can tell me and provide a link for the market potential for the Diltiazem cream? I think phase 3 results are quite likely and am curious how big of a pop we could see.
The regular daily swings in this stock from the high to the low of the day are pretty staggering. One can say that it's just a market correction or whatever, but the swings in this stock reveal a lot of day traders and manipulation, I think.
I wouldn't argue with you on that. lol All you have to do is look at the historical prices though to see how much this stock swings on a daily basis. It is kind of baffling to some extent because it has done this relatively daily over many months.
Not completely sure how the Uceris numbers are trending lately, but the big line I am looking for on top of growth is the $50 million mark. As was reported, that's when the profits will really start to impact the bottom line.
I think people are and should be excited about this drug referred to as a potential "blockbuster" by Proehl. However, searching the Santarus site and internet, though I know they raved about the results of the Phase I studies on the drug, I can't find any PR or article that discusses the results. I didn't know if this was common being that it was only a phase 1 study or if someone can provide a link to it?
lol....with all of these alleged millionares investing in SNTS and spending their days posting on yahoo message boards, this thing is bound to go up. Always slaves me why people feel the urge to tell people how many shares they supposedly bought. Must be an ego thing.
Couldn't it also be due to the price increase of Glumetza and Zegerid? Either way, I think we are good with Uceris.
I was in TSRX when the buyout occurred and it just seemed like there was always a sense that the company was going to be bought out soon due to the drug's effectiveness and how it compared to its peers. I am now in Durata and though things look very good considering the three phase III results, I don't sense the same anticipation or feeling as if the company will be acquired any time soon. Unlike Trius that was purchased before the FDA approval, do many feel that FDA approval will be the necessary component needed for companies to buy this company?
Realty excited about San 300. The praise and hype it has been given is intriguing. If phase 2 trials go well, I agree that the stock could really take off. Proehl has referred to it as a potential blockbuster so that has a lot of my interest.
Asoka, great first post. Lol. Actually, looking at your history of posts, it is quite an indicator of the lack of insight you are able to bring to a message board.
I see that Depo got royalties of 14.6 million from Glumetza sales this quarter after having royalties of 14.2 last quarter. Can one interpret that sales of Glumetza are around 45 million, which would be a slight increase? I honestly don't know and am asking what others think.
If sales of Uceris are approximately 21, Glumetza at 45, and Cycloset and Fenoglide are around 8, I am a little nervous about Zegerid that saw a loss in sales of 3 mil from 24 to 21, though the 8% price increase will help here. If all else stays the same, we still come in around 95, which should beat.
Though that is good news, just so people aren't mislead, those results were shown only in animal models at this time. Good news, but still very early stages.
I know it might be crazy for some to believe, but I am disappointed, actually. I've really enjoyed following this company and was really looking forward to the years to come, especially finding out the results of Sans-300 phase IIa. SNTS was the gift that kept on giving, really. I mean, it is difficult to find a company that provides the results like they did. When my sights were set on seeing it surpass new milestones and much higher pps, it is kind of a letdown. Had strongly contemplated buying another 1,000 shares today and thought I would wait til after earnings. lol Son of a...... I appreciate all of the insight fellow board members provided and will miss my fixation with checking these boards. Hope to catch on with you on another winner in the near future.
Kitty, though you may have been part of a buyout where another offer has come in, I haven't been so lucky. Man, I was a part of Kos when Abbot bought them out at a 56% premium. That was a great deal. I would feel much better with an offering at $40 pps. With the indications and potential new treatments for Uceris, San-300, and the new drugs coming through the pipeline, I really think $32 was not in the best interest of the SH.